Site web RHU COVIFERON

15 octobre 2025 Actualités

Nous sommes fiers de lancer le site web officiel du projet RHU COVIFERON, une initiative de recherche pionnière visant à faire progresser les thérapies antivirales et à améliorer les résultats pour les patients.
Vous y trouverez des informations sur notre mission, nos objectifs de recherche, nos études cliniques et nos équipes dédiées à l’innovation dans le domaine de la santé.

Restez connectés : nous partageons les actualités, les publications et les étapes clés du projet COVIFERON.
Ensemble, nous façonnons l’avenir de la science médicale.

Découvrez-en plus. Apprenez-en plus. Innovez avec nous.

Autres articles

Publications 2 mars 2026

Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza.

Avian influenza A virus (IAV) H5N1 is an emerging threat of human pandemic. We describe a 71-year-old man who died of H5N1 pneumonia in Louisiana and whose blood contained autoantibodies neutralizing type I IFNs (AAN-I-IFNs), including the 12 IFN-α subtypes [...]

Publications 2 mars 2026

Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis.

Fulminant viral hepatitis (FVH) is a devastating condition caused by hepatotropic viruses such as hepatitis A virus (HAV), hepatitis B virus (HBV), and HSV-1/2. We studied 149 FVH patients (73 males and 76 females, aged 1-76) for blood autoantibodies (auto-Abs) [...]

Publications 2 mars 2026

Expanding the scope of human immunology in the .

The publishes molecular, cellular, and clinical studies of patients with inborn errors of immunity, or their phenocopies, including autoimmune and somatic disorders. A central tenet in the field is that the current range of genetic immunological disorders is only [...]

Publications 2 mars 2026

Autoantibodies neutralizing type 1 interferons in two cohorts of people with HIV.

Autoantibodies (autoAbs) neutralizing type I interferons (IFN-I) markedly increase the risk of severe manifestations of some viral diseases. The prevalence of autoAbs neutralizing at least one IFN-I, specifically IFN-α2, IFN-β, and IFN-ω, in individuals from the Swiss human immunodeficiency virus [...]